

# Contribution of Acquired Carbapenem-Hydrolyzing Oxacillinases to Carbapenem Resistance in *Acinetobacter baumannii*

Claire Héritier,<sup>1</sup> Laurent Poirel,<sup>1</sup> Thierry Lambert,<sup>2</sup> and Patrice Nordmann<sup>1\*</sup>

Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, 94275 Le Kremlin-Bicêtre,<sup>1</sup> and Centre d'Etudes Pharmaceutiques, Châtenay-Malabry,<sup>2</sup> France

Received 2 February 2005/Returned for modification 21 March 2005/Accepted 30 May 2005

Carbapenem-hydrolyzing oxacillinases are reported increasingly in *Acinetobacter baumannii*. Since they hydrolyze carbapenems at low levels, the roles of carbapenem-hydrolyzing oxacillinases OXA-23, OXA-40, and OXA-58 in *A. baumannii* were determined. The *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-40</sub>, and *bla*<sub>OXA-58</sub> genes were inserted in broad-host-range plasmid pAT801 and transformed in *Escherichia coli* DH10B and in *A. baumannii* CIP 70.10 and its point mutant derivative *A. baumannii* BM4547, which overexpresses the efflux pump AdeABC. Natural plasmids harboring the *bla*<sub>OXA-23</sub> and *bla*<sub>OXA-58</sub> genes were also transformed in *A. baumannii* CIP 70.10. In addition, the *bla*<sub>OXA-40</sub> gene was inactivated at its chromosome location in *A. baumannii* CLA-1. Intermediate levels of resistance or reduced susceptibilities to carbapenems were observed for *A. baumannii* transformants expressing OXA-23, OXA-40, and OXA-58. The inactivation of *bla*<sub>OXA-40</sub> in *A. baumannii* CLA-1 yielded reduced susceptibilities to carbapenems. Carbapenem-hydrolyzing oxacillinases OXA-23, OXA-40, and to a lesser extent OXA-58 play a role in carbapenem resistance in *A. baumannii*, and overexpression of efflux pump AdeABC may also contribute to higher levels of resistance to  $\beta$ -lactams, including carbapenems.

*Acinetobacter baumannii* is frequently associated with nosocomial infections (3). Its acquired resistance to many antibiotics may complicate significantly the choice for antibiotic treatment (7, 17). *A. baumannii* naturally produces a cephalosporinase (5) that may be overexpressed due to insertion of insertion sequence (IS) IS<sub>Aba1</sub> that brings promoter sequences for its high level of expression (10, 29; L. Poirel, C. Héritier, and P. Nordmann, Abstr. 6th Int. Symp. Biol. *Acinetobacter*, abstr. pC4, 2004). However, overproduction of AmpC alone contributes to ceftazidime resistance but not to carbapenem resistance (5, 10, 29). Nevertheless, *A. baumannii* may acquire additional  $\beta$ -lactam resistance phenotypes, including carbapenem resistance.

Although carbapenem resistance may be due in part to an impaired permeability related to porin changes or to penicillin binding protein modifications (9, 13, 30), recent reports indicated that carbapenem-hydrolyzing  $\beta$ -lactamases may play a significant role (27). Carbapenem-hydrolyzing oxacillinases (Ambler class D  $\beta$ -lactamases) and metallo- $\beta$ -lactamases (Ambler class B  $\beta$ -lactamases) have been reported in *A. baumannii* (27, 31).

Seven oxacillinases with weak carbapenemase activity have been characterized in *A. baumannii*, including OXA-23, -24, -25, -26, -27, -40, and -58 from *A. baumannii* isolates in Scotland, Brazil, Spain, Belgium, Singapore, Portugal, and France (1, 4, 6, 11, 12, 14, 15, 19, 23, 26). These oxacillinases may be divided into three different groups. The  $\beta$ -lactamases OXA-23 and -27 share 99% amino acid identity, whereas they share 60% identity with a second group of oxacillinases consisting of OXA-24, -25, -26, and -40 that differ by a few amino acid

substitutions (1, 6, 15).  $\beta$ -Lactamase OXA-58 that by itself constitutes a third group of carbapenem-hydrolyzing oxacillinases is weakly related to the other oxacillinases sharing 48 and 47% amino acid identity with OXA-23 and OXA-24, respectively (26). Recently, a novel carbapenem-hydrolyzing oxacillinase, OXA-51, has been described in *A. baumannii* clinical isolates from Argentina (8). This oxacillinase shares less than 62 and 56% amino acid identity with OXA-40 and OXA-23, respectively (8). Its clinical role in carbapenem resistance of *A. baumannii* remains to be determined.

Since studies published on these oxacillinases reported mostly analyses of clinical isolates, it is difficult to compare the precise roles of these  $\beta$ -lactamases in resistance to carbapenems in *A. baumannii* (1, 15, 23, 26).

Thus, the aim of our study was to evaluate the roles of OXA-23, OXA-40, and OXA-58 taken as representatives of the three major groups of carbapenem-hydrolyzing oxacillinases for providing carbapenem resistance in *A. baumannii*, using reference and isogenic strains. Gene manipulations and expression studies have been performed not only in *Escherichia coli* but also in *A. baumannii*.

## MATERIALS AND METHODS

**Bacterial strains and plasmids.** *A. baumannii* clinical isolates FER and CLA-1 (15) were isolated at the Hôpital de Bicêtre (Le Kremlin-Bicêtre, France) in 2004 and 2001, respectively (Table 1). *A. baumannii* clinical isolate MAD was isolated in 2003 at the Ranguel hospital (Toulouse, France) (26) (Table 1). These isolates were identified by the API 20NE system (bioMérieux, Marcy l'Etoile, France) and by sequencing of 16S rRNA genes (data not shown).

*Escherichia coli* reference strain DH10B, *A. baumannii* CIP 70.10 (Pasteur Institute, Paris, France) and its point mutant derivative, *A. baumannii* BM4547 (which overexpresses the AdeABC efflux pump [20]), and shuttle plasmid pAT801 (16) were used for cloning experiments. *A. baumannii* CIP70.10 and *A. baumannii* BM4547 were also used in transformation experiments. Plasmid pCR-Blunt II-TOPO (Invitrogen, Cergy Pontoise, France) was used in inactivation experiments.

**Antimicrobial agents and MIC determinations.** The antimicrobial agents and their sources have been referenced elsewhere (2, 24). Antibiotic-containing disks

\* Corresponding author. Mailing address: Service de Bactériologie-Virologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France. Phone: 33-1-45-21-36-32. Fax: 33-1-45-21-63-40. E-mail: nordmann.patrice@bct.ap-hop-paris.fr.

TABLE 1. Strains and transformants used in this study

Strain	Origin	$\beta$ -Lactamase content	Reference
<i>A. baumannii</i> FER	Clinical strain	OXA-23 and AmpC	This study
<i>A. baumannii</i> CLA-1	Clinical strain	OXA-40 and AmpC	15
<i>A. baumannii</i> MAD	Clinical strain	OXA-58 and AmpC	26
<i>E. coli</i> DH10B <sup>a</sup>	Reference strain	AmpC ( <i>E. coli</i> )	15
<i>A. baumannii</i> CIP 70.10	Reference strain	AmpC	20
<i>A. baumannii</i> BM4547	Reference strain	AmpC	20
<i>E. coli</i> DH10B(pOXA-23)	Transformant	OXA-23	This study
<i>E. coli</i> DH10B(pOXA-40)	Transformant	OXA-40	This study
<i>E. coli</i> DH10B(pOXA-58)	Transformant	OXA-58	This study
<i>A. baumannii</i> CIP 70.10(pOXA-23)	Transformant	OXA-23 and AmpC	This study
<i>A. baumannii</i> CIP 70.10(pOXA-40)	Transformant	OXA-40 and AmpC	This study
<i>A. baumannii</i> CIP 70.10(pOXA-58)	Transformant	OXA-58 and AmpC	This study
<i>A. baumannii</i> BM4547(pOXA-23)	Transformant	OXA-23 and AmpC	This study
<i>A. baumannii</i> BM4547(pOXA-40)	Transformant	OXA-40 and AmpC	This study
<i>A. baumannii</i> BM4547(pOXA-58)	Transformant	OXA-58 and AmpC	This study
<i>A. baumannii</i> CIP 70.10(pFER)	Transformant	OXA-23 and AmpC	This study
<i>A. baumannii</i> CIP70.10(pMAD)	Transformant	OXA-58 and AmpC	26
<i>A. baumannii</i> BM4547(pFER)	Transformant	OXA-23 and AmpC	This study
<i>A. baumannii</i> BM4547(pMAD)	Transformant	OXA-58 and AmpC	This study
<i>A. baumannii</i> CLA-1 ( $\Delta$ OXA-40)	Recombinant strain	AmpC	This study

<sup>a</sup> As usual in *E. coli*, its naturally occurring *ampC* gene is not expressed.

were used for detection of antibiotic susceptibility with Mueller-Hinton agar plates and a disk diffusion assay (Sanofi-Diagnostics Pasteur, Marnes-La-Coquette, France) (www.sfm.fr). MICs were determined by an agar dilution technique as previously reported (24), and results were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards [NCCLS]) (22).

**Plasmid analysis and transformation.** Extraction of plasmid DNA from *A. baumannii* FER and *A. baumannii* MAD was attempted using the Kieser method (18). Plasmid suspensions were used for transformation experiments in *A. baumannii* CIP 70.10 using a Gene Pulser II electroporator (Bio-Rad, Ivry-sur-Seine, France) as previously described for *E. coli* (25). Electrotransformation products were selected on ticarcillin (50  $\mu$ g/ml)-containing plates.

**PCR experiments.** PCR experiments were performed as previously described (2, 28). The entire *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-40</sub>, and *bla*<sub>OXA-58</sub> genes, without their natural promoter and ribosome binding site (RBS) sequences, were amplified using combinations of primers OXA-23A and OXA-23B, OXA-40A and OXA-40B, and preOXA-58A and preOXA-58B, respectively (Table 2). The sizes of the corresponding PCR products were 840 bp, 846 bp, and 859 bp for the *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-40</sub>, and *bla*<sub>OXA-58</sub> genes, respectively. A 495-bp internal fragment of the *bla*<sub>OXA-40</sub> gene was generated with primers OXA-IMP1 and OXA-IMP2 for inactivation experiments (see below). Primers RA-1 and RA-2 (Table 2) were used to amplify a 603-bp fragment corresponding to the entire *arr-2* gene using the genomic DNA of *E. coli* MG-1 as the template (21). All PCR products were sequenced with an Applied Biosystems sequencer (ABI 3100).

**Cloning experiments.** The low-copy-number plasmid pAT801 conferring resistance to ampicillin was used as a shuttle vector able to replicate in *A. baumannii* and *E. coli*; it consists of part of pWH1266 and pUC18 (16). Inactivation

of the *bla*<sub>TEM-1</sub> gene of pAT801 was made using a PCR product corresponding to the entire *arr-2* gene inserted into the *ScaI*-restricted plasmid pAT801, giving rise to pAT801-RA conferring resistance to rifampin. PCR products corresponding to either the *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-40</sub>, or *bla*<sub>OXA-58</sub> gene then were inserted into the *EcoRI*- and *BamHI*-restricted plasmid pIM-1-RA under the control of the *lacZ* RBS and promoter sequences. This gave rise to recombinant plasmids pOXA-23, pOXA-40, and pOXA-58, which were transformed in *E. coli* DH10B, as described previously (25). Recombinant plasmids, extracted using the QIAGEN maxiprep kit (QIAGEN, Courtaboeuf, France), were transformed in *A. baumannii* CIP 70.10 and in *A. baumannii* BM4547. Transformants were selected on ticarcillin (50  $\mu$ g/ml)- and rifampin (25  $\mu$ g/ml)-containing plates.

**Gene inactivation.** Kanamycin-resistant plasmid pCR-BluntII-TOPO (Invitrogen, Cergy-Pontoise, France) unable to replicate in *A. baumannii* was used as a suicide vector. An internal fragment of the *bla*<sub>OXA-40</sub> gene, generated as described above, was inserted in the pCR-BluntII-TOPO using the Zero Blunt TOPO PCR Cloning kit (Invitrogen, Cergy Pontoise, France), giving rise to plasmid pTOPO-OXA-40. This plasmid was introduced in the kanamycin-susceptible *A. baumannii* CLA-1 strain by electrotransformation. Selection of *A. baumannii* CLA-1(pTOPO-OXA-40) was made on kanamycin (30  $\mu$ g/ml)-containing plates.

Inactivation of the *bla*<sub>OXA-40</sub> gene by insertion of pTOPO-OXA-40 was checked by PCR amplification using primers M13 reverse and OXA-40A (Table 2). The lack of production of  $\beta$ -lactamase OXA-40 in *A. baumannii* CLA-1 ( $\Delta$ OXA-40) was also verified by isoelectric focusing as previously described (15).

In order to complement *A. baumannii* CLA-1 ( $\Delta$ OXA-40) isolate, recombinant plasmid pOXA-40 was transformed in *A. baumannii* CLA-1 ( $\Delta$ OXA-40) as described previously (25). Selection of *A. baumannii* CLA-1 ( $\Delta$ OXA-40)

TABLE 2. Sequences of primers designed for this study

Primer	Sequence (5'→3') <sup>a</sup>	Location and/or primer type
RA-1	GCAGCCAAATCCCAACAATTAAGG	<i>arr-2</i>
RA-2	CGCCGCCATAAACGGCGACAGG	<i>arr-2</i> , reverse primer
OXA-23A	GGAATTCATGAATAAATATTTTACTTGC	<i>bla</i> <sub>OXA-23</sub>
OXA-23B	CGGGATCCC GTTAAATAATATTCAGGTC	<i>bla</i> <sub>OXA-23</sub> , reverse primer
OXA-40A	GGAATTCATGAAAAAATTTATACTTCC	<i>bla</i> <sub>OXA-40</sub>
OXA-40B	CGGGATCCC GTTAAATGATTTCCAAGATTTTCTAGCG	<i>bla</i> <sub>OXA-40</sub> , reverse primer
preOXA-58A	GGAATTCATGAAATTTATAAATTTGAGTTTTCAG	<i>bla</i> <sub>OXA-58</sub>
preOXA-58B	CGGGATCCC GTTATAAATAATGAAAAACACCC	<i>bla</i> <sub>OXA-58</sub> , reverse primer
OXA-IMP1	GCAATAMAGAAATATGTGTC	<i>bla</i> <sub>OXA-40</sub> , internal primer
OXA-IMP2	CTCMACCCARCCRTGCAACC	<i>bla</i> <sub>OXA-40</sub> , internal reverse primer
M13 reverse	GTCCTTTGTCTGATACT	pCR-BluntII-TOPO reverse sequencing primer

<sup>a</sup> M is A or C, S is G or C, and R is A or G.

TABLE 3. MICs of  $\beta$ -lactams for *A. baumannii* strains

$\beta$ -Lactam <sup>a</sup>	MIC ( $\mu\text{g/ml}$ ) of $\beta$ -lactam for <i>A. baumannii</i> strain <sup>b</sup> :										
	FER (OXA-23)	CIP 70.10 (pFER)	BM4547 (pFER)	CLA-1 (OXA-40)	CLA-1 ( $\Delta$ OXA-40)	CLA-1 ( $\Delta$ OXA-40) (pOXA-40)	MAD (OXA-58)	CIP 70.10 (pMAD)	BM4547 (pMAD)	CIP 70.10	BM4547
AMX	>256	>256	>256	>256	>256	>256	>256	>256	>256	32	64
TIC	>256	>256	>256	>256	128	>256	>256	>256	>256	4	8
CAZ	>32	4	4	>32	>32	>32	>32	2	4	2	4
CTX	>32	16	>32	>32	>32	>32	32	8	>32	8	>32
FEP	>32	>32	>32	>32	32	>32	>32	1	>32	1	>32
CPO	>32	>32	>32	>32	>32	>32	>32	8	>32	2	>32
ATM	128	64	64	128	128	128	32	16	16	16	16
IPM	>32	16	>32	>32	2	>32	32	2	32	0.25	0.5
MEM	>32	16	>32	>32	4	>32	>32	2	32	0.25	0.5

<sup>a</sup> AMX, amoxicillin; TIC, ticarcillin; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; CPO, cefpirome; ATM, aztreonam; IPM, imipenem; MEM, meropenem.

<sup>b</sup> MICs of  $\beta$ -lactams for *A. baumannii* FER (OXA-23), *A. baumannii* CIP 70.10 and *A. baumannii* BM4547 harboring natural plasmid pFER, *A. baumannii* CLA-1 (OXA-40), *A. baumannii* CLA-1 ( $\Delta$ OXA-40) and *A. baumannii* CLA-1 ( $\Delta$ OXA-40) harboring recombinant plasmid pOXA-40, *A. baumannii* MAD (OXA-58), *A. baumannii* CIP 70.10 and *A. baumannii* BM4547 harboring natural plasmid pMAD, and *A. baumannii* CIP 70.10 and *A. baumannii* BM4547 reference strains.

(pOXA-40) was made on ticarcillin (50  $\mu\text{g/ml}$ )-, rifampin (25  $\mu\text{g/ml}$ )-, and kanamycin (30  $\mu\text{g/ml}$ )-containing plates.

## RESULTS AND DISCUSSION

**Antibiotic susceptibility and plasmid analyses.** *A. baumannii* clinical isolates FER, CLA-1, and MAD produced the  $\beta$ -lactamases OXA-23, OXA-40, and OXA-58, respectively (15, 26). They were resistant to all  $\beta$ -lactams, including carbapenems (Table 3).

Plasmid extractions of *A. baumannii* FER and *A. baumannii* MAD revealed a ca. 70-kb plasmid and a 30-kb plasmid (26), respectively, whereas no plasmid was detected in *A. baumannii* CLA-1 (15). These plasmids were extracted and then electrotransformed in *A. baumannii* CIP 70.10 and in its point mutant derivative, *A. baumannii* BM4547, which overexpresses the AdeABC efflux pump. *A. baumannii* CIP 70.10(pFER) and *A. baumannii* BM4547(pFER) transformants, were resistant to ticarcillin, imipenem, and meropenem, with a higher level of carbapenem resistance for *A. baumannii* BM4547(pFER) (Table 3). *A. baumannii* CIP 70.10(pMAD) transformant, was resistant to ticarcillin and had a reduced susceptibility to imipenem and meropenem, whereas the *A. baumannii* BM4547(pMAD) transformant was resistant to imipenem and meropenem (Table 3). These results indicated that overexpression of the AdeABC efflux pump and expression of OXA-23 or OXA-58 led to higher levels of carbapenem resistance.

**Cloning and expression of the carbapenem-hydrolyzing oxacillinase genes in *E. coli*.** After PCR amplification, the *bla*<sub>OXA-23</sub>, *bla*<sub>OXA-40</sub>, and *bla*<sub>OXA-58</sub> genes were inserted into the rifampin-resistant vector pAT801-RA under the control of the *lacZ* RBS and promoter sequences and expressed in *E. coli* DH10B. Antibiotic susceptibility testing revealed that these *E. coli* recombinant strains had a  $\beta$ -lactam resistance that include reduced susceptibility to imipenem (Table 4).

**Expression of the carbapenem-hydrolyzing oxacillinase genes in *A. baumannii*.** Recombinant plasmids pOXA-23, pOXA-40, and pOXA-58 were then electrotransformed in *A. baumannii* CIP 70.10. High-level resistance to ticarcillin and susceptibility to ceftazidime was observed for all transformants, as expected for this type of oxacillinases (15, 23, 26). Reduced susceptibilities to imipenem and meropenem were

observed for *A. baumannii* CIP 70.10(pOXA-23) and *A. baumannii* CIP 70.10(pOXA-40), and *A. baumannii* CIP 70.10(pOXA-58) was susceptible to these antibiotics (Table 4). Thus, OXA-58 conferred only very weak reduced susceptibilities to carbapenems once expressed in *A. baumannii*, by contrast to OXA-23 and OXA-40. Recombinant plasmids pOXA-23, pOXA-40, and pOXA-58 were then electrotransformed in *A. baumannii* BM4547, which overexpresses the efflux pump AdeABC. *A. baumannii* BM4547(pOXA-23) and *A. baumannii* BM4547(pOXA-40) had intermediate levels of resistance to imipenem and meropenem (Table 4), whereas only a slight increase of carbapenem resistance in *A. baumannii* BM4547(pOXA-58) was observed (Table 4). These results showed that overexpression of the AdeABC efflux pump associated with expression of these oxacillinases induced a higher level of carbapenem resistance.

These discrepancies suggested that the kinetics of these oxacillinases were more complex, since they are supposed to have similar hydrolytic activities for these substrates (15, 23, 26). Note that since *bla*<sub>OXA-23</sub> and *bla*<sub>OXA-58</sub> have been found in association with IS elements, it is likely that these structures provided higher levels of expression for OXA-23 and OXA-58 in *A. baumannii*.

**Inactivation of *bla*<sub>OXA-40</sub>.** In order to determine the precise role of the chromosomally located  $\beta$ -lactamase OXA-40 in carbapenem resistance of *A. baumannii* CLA-1, inactivation of the *bla*<sub>OXA-40</sub> gene was performed. After transformation of the pTOPO-OXA-40 recombinant plasmid into *A. baumannii* CLA-1 and selection on kanamycin-containing plates, *A. baumannii* CLA-1 ( $\Delta$ OXA-40) was obtained. We checked that *A. baumannii* CLA-1 ( $\Delta$ OXA-40) did not express OXA-40 by isoelectric focusing compared to results obtained with culture of *A. baumannii* CLA-1. A culture extract of *A. baumannii* CLA-1 subjected to isoelectric focusing gave two  $\beta$ -lactamases with pIs of 8.6 and 9.4, which correspond to the pIs of OXA-40 and AmpC, respectively, whereas a culture extract of *A. baumannii* CLA-1 ( $\Delta$ OXA-40) gave only one  $\beta$ -lactamase with a pI of 9.4, which corresponds to the pI of AmpC (data not shown). Inactivation of the *bla*<sub>OXA-40</sub> gene resulted in susceptibility to carbapenems (Table 3), thus showing the contributive role of OXA-40 in carbapenem resistance. This result was

confirmed, as resistance to carbapenems was restored in *A. baumannii* CLA-1 ( $\Delta$ OXA-40) (pOXA-40) by complementing the phenotype with the expression of OXA-40 (Table 3).

**Conclusion.** This study demonstrated that carbapenem-hydrolyzing oxacillinases contribute significantly to resistance to carbapenems in *A. baumannii*. *A. baumannii* transformants with natural plasmid pFER or pMAD, producing either  $\beta$ -lactamase OXA-23 or OXA-58, had higher levels of carbapenem resistance than *A. baumannii* transformants with recombinant plasmid pOXA-23 or pOXA-58 producing the same oxacillinase. Thus, in vivo association of *bla*<sub>OXA-23</sub> and *bla*<sub>OXA-58</sub> genes with insertion sequence elements *ISAbal* and *ISAbas3*, respectively (10, 26, 29), were likely responsible for their higher levels of expression in *A. baumannii* by providing strong promoter sequences. Finally, overexpression of efflux pump AdeABC of *A. baumannii* contributed significantly to the high level of resistance to most  $\beta$ -lactams, including carbapenems. Further work may determine whether this effect is direct or indirect through changes of outer membrane proteins.

**ACKNOWLEDGMENTS**

This work was funded by a grant from the Ministère de l'Éducation Nationale et de la Recherche (UPRES-EA3539) and Université Paris XI, Paris, France, and by the European Community (6th PCRD, LSHM-CT-2003-503-335). L.P. is a researcher from the INSERM, Paris, France.

**REFERENCES**

1. Afzal-Shah, M., N. Woodford, and D. M. Livermore. 2001. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D  $\beta$ -lactamases associated with carbapenem resistance in clinical isolates of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **45**:583-588.
2. Aubert, D., L. Poirel, J. Chevalier, S. Léfouard, J.-M. Pagès, and P. Nordmann. 2001. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **45**:1615-1620.
3. Bergogne-Bérézin, E., and K. J. Towner. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin. Microbiol. Rev.* **9**:148-165.
4. Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. M. Martinez-Beltran. 2000. Characterization of a nosocomial outbreak by a multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in *A. baumannii* is not due solely to the presence of  $\beta$ -lactamases. *J. Clin. Microbiol.* **38**:3299-3305.
5. Bou, G., and J. Martinez-Beltran. 2000. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC  $\beta$ -lactamase in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **44**:428-432.
6. Bou, G., A. Oliver, and J. Martinez-Beltran. 2000. OXA-24, a novel class D  $\beta$ -lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob. Agents Chemother.* **44**:1556-1561.
7. Brown, S., C. Bantar, H. K. Young, and S. G. Amyes. 1998. Limitation of *Acinetobacter baumannii* treatment by plasmid-mediated carbapenemase ARI-2. *Lancet* **351**:186-187.
8. Brown, S., H. K. Young, and S. G. Amyes. 2005. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clin. Microbiol. Infect.* **11**:15-23.
9. Clark, R. B. 1996. Imipenem resistance among *Acinetobacter baumannii*: association with reduced expression of a 33-36 kDa outer membrane protein. *J. Antimicrob. Chemother.* **38**:245-251.
10. Corvec, S., N. Caroff, E. Espaze, C. Giraudeau, H. Drugeon, and A. Reynaud. 2003. AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J. Antimicrob. Chemother.* **52**:629-635.
11. Dalla-Costa, L. B., J. M. Coelho, H. A. Souza, M. E. S. Castro, C. J. N. Stier, K. L. Bragagnolo, A. Rea-Neto, S. R. Pentead-Filho, D. M. Livermore, and N. Woodford. 2003. Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil. *J. Clin. Microbiol.* **41**:3403-3406.
12. Donald, H. M., W. Scaife, S. G. Amyes, and H. K. Young. 2000. Sequence analysis of ARI-1, a novel OXA  $\beta$ -lactamase, responsible for imipenem resistance in *Acinetobacter baumannii* 6B92. *Antimicrob. Agents Chemother.* **44**:196-199.
13. Gehrlein, M., H. Leying, W. Cullmann, S. Wendt, and W. Opferkuch. 1991.

TABLE 4. MICs of  $\beta$ -lactams for *E. coli* and *A. baumannii* strains

$\beta$ -Lactam <sup>a</sup>	<i>E. coli</i>						<i>A. baumannii</i>					
	DH10B (pOXA-23)	DH10B (pOXA-40)	DH10B (pOXA-58)	DH10B (pAT801-RA)	CIP 70.10 (pOXA-23)	CIP 70.10 (pOXA-40)	CIP 70.10 (pOXA-58)	CIP 70.10 (pAT801-RA)	BM4547 (pOXA-23)	BM4547 (pOXA-40)	BM4547 (pOXA-58)	BM4547 (pAT801-RA)
AMX	>256	>256	>256	4	>256	>256	>256	32	>256	>256	>256	64
TIC	>256	>256	>256	4	>256	>256	>256	4	>256	>256	>256	8
CAZ	0.06	0.06	0.06	0.06	4	4	4	2	4	4	4	
CTX	0.12	0.12	0.12	0.12	16	16	16	8	>32	>32	>32	
FEP	0.12	0.12	0.12	0.06	2	2	2	1	>32	>32	>32	
CPO	0.12	0.12	0.12	0.12	4	4	2	2	>32	>32	>32	
ATM	0.12	0.12	0.12	0.12	16	16	16	16	16	16	16	
IPM	0.25	0.5	0.25	0.06	4	4	0.5	0.25	8	8	0.5	
MEM	0.06	0.06	0.06	0.06	4	4	0.5	0.25	8	8	0.5	

<sup>a</sup> AMX, amoxicillin; TIC, ticarcillin; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; CPO, cephrone; ATM, aztreonam; IPM, imipenem; MEM, meropenem. MICs of  $\beta$ -lactams for *E. coli* DH10B harboring recombinant plasmid pOXA-23, pOXA-40, or pOXA-58; *E. coli* DH10B reference strain harboring plasmid pAT801-RA; *A. baumannii* CIP 70.10 harboring recombinant plasmid pOXA-23, pOXA-40, or pOXA-58; *A. baumannii* CIP 70.10 reference strain harboring plasmid pAT801-RA; *A. baumannii* BM4547 harboring recombinant plasmid pOXA-23, pOXA-40 or pOXA-58; and *A. baumannii* BM4547 reference strain harboring plasmid pAT801-RA.

- Imipenem resistance in *Acinetobacter baumannii* is due to altered penicillin binding protein. *Chemotherapy* **37**:405–412.
14. Héritier, C., A. Dubouix, L. Poirel, N. Marty, and P. Nordmann. 2005. A nosocomial outbreak of *Acinetobacter baumannii* isolates expressing the carbapenem-hydrolyzing oxacillinase OXA-58. *J. Antimicrob. Chemother.* **55**: 115–118.
  15. Héritier, C., L. Poirel, D. Aubert, and P. Nordmann. 2003. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **47**:268–273.
  16. Hunger, M., R. Schmucker, V. Kishan, and W. Hillen. 1990. Analysis and nucleotide sequence of an origin of DNA replication in *Acinetobacter calcoaceticus* and its use for *Escherichia coli* shuttle plasmids. *Gene* **87**:45–51.
  17. Joly-Guillou, M. L., E. Bergogne-Berezin, and J. F. Vieu. 1990. Epidemiology of *Acinetobacter* and resistance to antibiotics at hospitals. A 5-year evaluation. *Presse Med.* **19**:357–361.
  18. Kieser, T. 1984. Factors affecting the isolation of CCC DNA from *Streptomyces lividans* and *Escherichia coli*. *Plasmid* **12**:19–36.
  19. Lopez-Otsoa, F., L. Gallego, K. J. Towner, L. Tysall, N. Woodford, and D. M. Livermore. 2002. Endemic carbapenem resistance associated with OXA-40 carbapenemase among *Acinetobacter baumannii* isolates from a hospital in northern Spain. *J. Clin. Microbiol.* **40**:4741–4743.
  20. Marchand, I., L. Damier-Piolle, P. Courvalin, and T. Lambert. 2004. Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system. *Antimicrob. Agents Chemother.* **48**:3298–3304.
  21. Naas, T., Y. Mikami, T. Imai, L. Poirel, and P. Nordmann. 2001. Characterization of In53, a class 1 plasmid- and composite transposon-located integron of *Escherichia coli* which carries an unusual array of gene cassettes. *J. Bacteriol.* **183**:235–249.
  22. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, p. 1. Approved standard M7-A6. NCCLS, Wayne, Pa.
  23. Paton, R., R. S. Miles, J. Hood, and S. G. B. Amyes. 1993. ARI-1:  $\beta$ -lactamase mediated imipenem resistance in *Acinetobacter baumannii*. *Int. J. Antimicrob. Agents* **2**:81–88.
  24. Philippon, L. N., T. Naas, A.-T. Bouthors, V. Barakett, and P. Nordmann. 1997. OXA-18, a class D clavulanic acid-inhibited extended-spectrum  $\beta$ -lactamase from *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **41**: 2188–2195.
  25. Poirel, L., D. Girlich, T. Naas, and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10  $\beta$ -lactamase from *Pseudomonas aeruginosa* and its plasmid- and integron-located gene. *Antimicrob. Agents Chemother.* **45**:447–453.
  26. Poirel, L., S. Marqué, C. Héritier, C. Segonds, G. Chabanon, and P. Nordmann. 2005. OXA-58, a novel class D  $\beta$ -lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **49**:202–208.
  27. Poirel, L., and P. Nordmann. 2002. Acquired carbapenem-hydrolyzing  $\beta$ -lactamases and their genetic support. *Curr. Pharm. Biotechnol.* **3**:117–127.
  28. Sambrook, J., and D. W. Russell. 2001. *Molecular cloning: a laboratory manual*, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  29. Segal, H., E. C. Nelson, and B. G. Elisha. 2004. Genetic environment of *ampC* in an *Acinetobacter baumannii* clinical isolate. *Antimicrob. Agents Chemother.* **48**:612–614.
  30. Urban, C., E. S. Go, K. S. Meyer, N. Mariano, and J. J. Rahal. 1995. Interactions of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible *Acinetobacter baumannii*. *FEMS Microbiol. Lett.* **125**:193–197.
  31. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo- $\beta$ -lactamases: the quiet before the storm? *Clin. Microbiol. Rev.* **18**:306–325.